On the other hand, a pooled analysis of 37 studies reported that slow NAT2 acetylators had increased the risk for the development of anti-TB drug-induced liver injury (AT-DILI) compared to non-slow NAT2 acetylators (intermediate and fast NAT2 acetylators) (overall odds ratio (OR) = 3.15 (95% CI 2.58–3.84, heterogeneity measure (I2) = 51.3%, p = 0.000)) in TB patients [10]. This evidence concerns the gene NAT2 and tuberculosis.